Desmopressin Melt Therapy in Nocturnal Polyuria Patients: Pharmacodynamic Study

Nocturia Clinical Trial

Official title:

Desmopressin Melt Therapy in Nocturnal Polyuria Patients: Pharmacodynamic Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01439997
• Other study ID #: 2011/567
• Status: Completed
• Phase: Phase 4
• Start date: March 26, 2012
• Est. completion date: February 1, 2015

Study information

• Verified date: December 2022
• Source: University Hospital, Ghent
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to find out what the pharmacodynamic (PD) characteristics of desmopressin melt are in nocturia patients (compared to healthy volunteers and children). The main questions the investigators want to answer are:

• Are differences related to the pathophysiological factors involved in nocturia?

• Are there age/gender/size differences?

• Can the investigators identify patients who are likely to develop hyponatraemia?

• Can the investigators individualize treatment and reduce risk for hyponatraemia?

The patient will be given a prescription to buy Minirin Melt 60µg at the local pharmacy. During 30 days, the patient has to take Minirin Melt 60µg in the evening before going to bed.

There are two groups of patients:

Group A:

Patients that still have to undergo an evaluation phase, according to standard procedures (e.g. osmolality test, blood sample). This procedure is not a part of this study. The study starts when the 1st Minirin Melt tablet has been taken (= day 1).

Group B:

This group already went through the evaluation phase (by participation to study 1 or study 3 as mentioned above) and they have been prescribed Minirin Melt 60 µg ambulatory.

The study starts when the patients takes his first prescribed Minirin Melt tablet:

• On day 3 and day 7 a blood sample will be taken at the UZ Ghent for safety control (Na+, K+, creatinin, osmolality = good clinical practice guideline). These first 2 visits (day 3 and day 7) are standard procedure. If the patient is at high risk for side effects, blood has to be taken during the first 7 days.

• On day 3 the patient has to give a urine sample.

• Patients have to fill out a frequency/volume chart during the first 14 days.

• On day 30, a 3rd blood sample will be taken

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5
• Est. completion date: February 1, 2015
• Est. primary completion date: February 1, 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• written informed consent prior to the performance of any study-related activity

• patients, men and women, 18 years and older, with an average of = 2 nocturnal voids per night

• evidence for nocturnal polyuria (nocturnal urine volume >33% of total volume over 24h), determined on frequency/volume chart

• Diuresis <2.5L

Exclusion Criteria:

• hypersensitivity/anaphylactic reaction on desmopressin or one of the other substances

• pregnancy

• genitourinary tract pathology (infection, tumor,...)

• urolithiasis

• suspicion or evidence of cardiac failure

• moderate to severe renal insufficiency (creatinin clearance < 60 ml/min)

• psychogenic or habitual polydipsia

• hyponatraemia or predisposition for hyponatraemia

• diabetes insipidus

• syndrome of inadequate ADH production

• suspicion or evidence of liver failure

Related Conditions & MeSH terms

• Nocturia
• Polyuria

Intervention

Drug:
• Desmopressin
Administration of minirin melt 60 µg: desmopressin (acetate) 60 µg oral lyophilisate.

Locations

Country	Name	City	State
Belgium	University Hospital Ghent	Ghent

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Ghent

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood samples for plasma concentration of Na+, K+, creatinin, osmolality (safety profile)at day 3.		At day 3 after first desmopressin intake.
Primary	Urine sample for urine concentration of Na+, K+, creatinin and osmolality		At day 3
Primary	Area Under Curve (AUC) frequency/volume chart during the first 14 days		Every day during the first 14 days.
Primary	The decrease of number of nocturnal micturition episodes.	Questionnaires at day 0 to evaluate the decrease of number of nocturnal micturition episodes.	At day 0
Primary	The decrease of the number of nocturnal micturition episodes.	Questionnaires at day 30 to evaluate the number of nocturnal micturition episodes	At day 30
Primary	Registration of number of side effects at day 3.		At day 3
Primary	Blood samples for plasma concentration of Na+, K+, creatinin, osmolality (safety profile)at day 7.		At day 7 after first desmopressin intake
Primary	Blood samples for plasma concentration of Na+, K+, creatinin, osmolality (safety profile)at day 30.		At day 30 after first desmopressin intake
Primary	Registration of number of side effects at day 7		At day 7
Primary	Registration of number of side effects at day 30.		At day 30

External Links

•   Related Info